このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

2026年9月24日 更新者:Kristen Barbour、Scripps Translational Science Institute

A Site-Less Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

The purpose of this study is to evaluate the feasibility of a site-less (fully remote) clinical trial using phenylbutyrate for SLC6A1-related disorders. Study participants will receive treatment with phenylbutyrate, undergo electroencephalogram (EEG) monitoring, and complete laboratory testing. Caregivers will report seizure frequency, answer questionnaires, and report side effects.

Participants will be randomly assigned to one of two groups. Randomization is stratified by age band (<7 years vs. ≥7 years) and baseline seizure frequency (≤5 vs. >5 daily seizures). One group will begin treatment immediately; the other group will have a 6-week observation period before starting treatment. All participants will receive phenylbutyrate. Treatment lasts up to 18 weeks with the option to extend for up to 3 years. Follow-up occurs at 18 weeks. If extending treatment, additional follow-up occurs at 6 months, 1 year, and then annually.

Participation is completely voluntary. There is the risk of adverse events from the study drug, phenylbutyrate, including hospitalization from metabolic acidosis. There is the risk of loss of confidentiality of your medical and personal information collected for this study. This study does not replace emergency medical care.

This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

調査の概要

状態

募集

条件

詳細な説明

The purpose of this study is to determine whether a site-less (fully remote) clinical trial design, one conducted entirely remotely without a physical clinic site, is feasible for families affected by SLC6A1-related disorders. A secondary purpose is to explore the safety, tolerability, and preliminary effectiveness of phenylbutyrate in this population.

SLC6A1-related disorder is a rare genetic condition that causes epilepsy and intellectual disability. It is caused by variants in the SLC6A1 gene, which encodes a protein called GABA transporter 1 (GAT-1) that helps regulate the brain chemical gamma-aminobutyric acid (GABA). Phenylbutyrate is a medication that is Food and Drug Administration (FDA) -approved for a different condition (urea cycle disorders) and is being studied here for its potential antiseizure effects in SLC6A1-related disorders. Early studies have suggested that phenylbutyrate may reduce seizure frequency in some individuals with this condition, but it has not yet been studied in a controlled clinical trial. This study will help determine whether a larger, controlled trial is feasible using a site-less (fully remote) design and will provide early information about how well phenylbutyrate works and how well it is tolerated in this population.

研究の種類

介入

入学 (推定)

20

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • San Diego、California、アメリカ、92130
        • 募集
        • Scripps Research Translational Institute
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

2年~60年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Confirmed diagnosis of SLC6A1-related disorder based on a pathogenic or likely pathogenic variant in the SLC6A1 gene
  • Age 2-60 years at time of consent
  • Active clinical seizures, defined as ≥4 seizures in the 4 weeks prior to enrollment
  • Seizures persisting despite an adequate trial of ≥2 prior antiseizure medications at therapeutic doses
  • Stable antiseizure medication regimen for ≥4 weeks prior to enrollment
  • Parent, legal guardian, or legally authorized representative (LAR) able to provide informed consent and participate in digital follow-up assessments
  • Local licensed physician identified for ordering laboratory testing, EEG, and clinical evaluation as needed
  • English-speaking caregiver for consent and study communication

Exclusion Criteria:

  • Larger 3p25 chromosomal deletion extending beyond SLC6A1 and SLC6A11 to encompass additional genes
  • Early-infantile developmental and epileptic encephalopathy (DEE) phenotype
  • Epileptic spasms within the 6 months prior to enrollment
  • Hepatic impairment (AST or ALT >2× the upper limit of normal)
  • Renal impairment (eGFR <60 mL/min/1.73m²)
  • Thrombocytopenia (platelet count <150 × 10³/μL)
  • Inborn errors of beta-oxidation
  • Pancreatic insufficiency or intestinal malabsorption
  • Known hypersensitivity to phenylbutyrate or any of its components
  • Participation in another interventional investigational study within 30 days or 5 half-lives of the investigational product, whichever is longer
  • Current use of alfentanil, quinidine, cyclosporine, or probenecid due to clinically significant interactions with phenylbutyrate based on CYP3A4 modulation
  • Pregnancy or breastfeeding
  • Any condition that in the investigator's judgment would interfere with study participation or safety monitoring

This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm A (Immediate Start)

Arm A will receive immediate treatment with phenylbutyrate beginning week 0 through week 18.

Glycerol phenylbutyrate oral liquid (1.1 g/mL) administered orally three times daily with food or formula, or via gastrostomy or nasogastric tube when clinically indicated. The dose is titrated over 8 weeks from a starting dose of 3.6 mL/m²/day to a target maximum of 11.2 mL/m²/day (12.4 g/m²/day), not to exceed 17.5 mL/day total, based on body surface area. Dose adjustments are made based on tolerability and safety laboratory results. Drug is obtained through self-pay via Cost Plus pharmacy with direct home delivery, or through the participant's health insurance at a designated pharmacy.

Other Name(s): Ravicti; glycerol phenylbutyrate oral liquid; GPB; 4-phenylbutyrate; 4-PBA

アクティブコンパレータ:Arm B (Delayed Start)

Arm B will have a delayed start with an observation period weeks 0-6 followed by treatment beginning at week 6 through week 18.

Glycerol phenylbutyrate oral liquid (1.1 g/mL) administered orally three times daily with food or formula, or via gastrostomy or nasogastric tube when clinically indicated. The dose is titrated over 8 weeks from a starting dose of 3.6 mL/m²/day to a target maximum of 11.2 mL/m²/day (12.4 g/m²/day), not to exceed 17.5 mL/day total, based on body surface area. Dose adjustments are made based on tolerability and safety laboratory results. Drug is obtained through self-pay via Cost Plus pharmacy with direct home delivery, or through the participant's health insurance at a designated pharmacy.

Other Name(s): Ravicti; glycerol phenylbutyrate oral liquid; GPB; 4-phenylbutyrate; 4-PBA

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Recruitment efficiency
時間枠:From study opening through end of enrollment (approximately 2 years)

Number of participants enrolled and time from first contact to consent, averaged across the enrollment period. Target: ≥20 participants enrolled over 24 months.

From study opening through end of enrollment (approximately 2 years)
Protocol adherence: seizure diary completion
時間枠:Weeks 0-18

Proportion of weekly seizure diary entries completed at scheduled intervals across the 18-week assessment period. Target: ≥80% of scheduled entries completed.

Weeks 0-18
Protocol adherence: Electroencephalogram (EEG) completion
時間枠:Baseline, week 6 and week 18

Proportion of participants completing baseline, week 6, and 18-week EEG as specified by protocol. Target: ≥80%.

Baseline, week 6 and week 18
Protocol adherence: side effect questionnaire completion
時間枠:From treatment initiation through week 18

Proportion of scheduled side effect questionnaires completed at protocol-specified intervals from treatment initiation through week 18. Target: ≥80%.

From treatment initiation through week 18
Protocol adherence: safety laboratory completion
時間枠:6 weeks after treatment initiation

Proportion of participants completing scheduled safety laboratory testing at 6 weeks after treatment initiation. Target: ≥80%.

6 weeks after treatment initiation
Retention
時間枠:Week 18

Proportion of enrolled participants completing the 18-week assessment period without voluntary or involuntary withdrawal. Target: ≥80%.

Week 18
Caregiver satisfaction: overall satisfaction
時間枠:Week 18

Median score on User Experience Questionnaire item Q1 assessing overall satisfaction with remote clinical trial participation. Scale 1-5 (1=very dissatisfied, 5=very satisfied). Target: median ≥4.

Week 18
Caregiver satisfaction: acceptability
時間枠:Week 18

Proportion of caregivers responding "Yes" to User Experience Questionnaire item Q2 asking whether they would recommend participating in a remote clinical trial to other families. Target: ≥80%.

Week 18
Caregiver satisfaction: fit with daily routine
時間枠:Week 18

Median score on User Experience Questionnaire item Q3 assessing whether the study fit well into the family's daily routine. Scale 1-5 (1=not at all, 5=completely). Target: median ≥4.

Week 18
Caregiver satisfaction: clarity of study procedures
時間枠:Week 18

Median score on User Experience Questionnaire item Q4 assessing ease of understanding study procedures and requirements. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

Week 18
Caregiver satisfaction: time burden
時間枠:Week 18

Median score on User Experience Questionnaire item Q5 assessing ease of finding time to complete study tasks. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

Week 18
Caregiver satisfaction: study team communication
時間枠:Week 18

Median score on User Experience Questionnaire item Q6 assessing clarity and helpfulness of study team communication. Scale 1-5 (1=not at all clear/helpful, 5=extremely clear/helpful). Target: median ≥4.

Week 18
Caregiver satisfaction: adequacy of remote safety monitoring
時間枠:Week 18

Median score on User Experience Questionnaire item Q7 assessing whether the participant's safety was adequately monitored during the remote trial. Scale 1-5 (1=not at all, 5=completely). Target: median ≥4.

Week 18
Caregiver satisfaction: access to medical support
時間枠:Week 18

Median score on User Experience Questionnaire item Q8 assessing ease of accessing medical support or advice when needed. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.

Week 18
Caregiver satisfaction: Research Electronic Data Capture (REDCap) usability
時間枠:Week 18

Median score on User Experience Questionnaire item Q9 assessing comfort using the REDCap platform for study participation. Scale 1-5 (1=very uncomfortable, 5=very comfortable). Target: median ≥4.

Week 18
Caregiver satisfaction: instructional video usefulness
時間枠:Week 18

Median score on User Experience Questionnaire item Q10 assessing usefulness of instructional videos provided through REDCap. Scale 1-5 (1=not at all useful, 5=extremely useful). Target: median ≥4.

Week 18
Caregiver satisfaction: optional phone call helpfulness
時間枠:4 weeks after treatment initiation

Median score on User Experience Questionnaire item Q12 among participants who participated in the optional phone call at 4 weeks after treatment initiation (Q11=Yes). Scale 1-5 (1=not at all helpful, 5=extremely helpful). Proportion participating reported separately. Target: median ≥4 among participants.

4 weeks after treatment initiation
Caregiver experience: facilitators and barriers
時間枠:Week 18

Thematic summary of free-text responses to User Experience Questionnaire items Q13 (what participants liked most) and Q14 (challenges faced). Analyzed qualitatively to identify themes relevant to remote trial design.

Week 18

二次結果の測定

結果測定
メジャーの説明
時間枠
Seizure frequency: percent change from baseline
時間枠:Baseline through week 18

Percent change in average weekly seizure frequency from the baseline observation period to weeks 14-18 of treatment (stable dose period), based on caregiver-completed seizure diaries. Analyzed descriptively.

Baseline through week 18
Seizure frequency: responder rate
時間枠:Baseline through week 18

Proportion of participants achieving ≥50% reduction in average weekly seizure frequency from baseline to the stable dose period (weeks 14-18 of treatment). Analyzed descriptively.

Baseline through week 18
Caregiver Global Impression of Change (CGIC)
時間枠:Week 18

Caregiver-rated global impression of change since starting phenylbutyrate, assessed using a 7-point scale (1=very much improved, 7=very much worse). Analyzed descriptively.

Week 18
Adaptive behavior: Vineland Adaptive Behavior Scales, Third Edition (VABS-3) composite score
時間枠:Baseline and week 18

Change in VABS-3 Adaptive Behavior Composite score from baseline to week 18. Standard scores range 20-160; higher scores indicate better adaptive functioning. Analyzed descriptively.

Baseline and week 18
Behavior: Aberrant Behavior Checklist Community Version
時間枠:Baseline and Week 18

Change in total score and subscale scores (Irritability/Agitation, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance, Inappropriate Speech) from baseline to week 18. Total scores range 0-174; higher scores indicate more frequent or severe behavioral difficulties. Analyzed descriptively.

Baseline and Week 18
Quality of life: QI-Disability score
時間枠:Baseline and week 18

Change in Quality of Life Inventory-Disability (QI-Disability) total score from baseline to week 18. Scores range 0-100; higher scores indicate better quality of life. Analyzed descriptively.

Baseline and week 18
Medication Burden
時間枠:Baseline and Week 18

Change in the number of concomitant antiseizure medications (not counting glycerol phenylbutyrate) from baseline to week 18, captured via weekly seizure diary. Analyzed descriptively.

Baseline and Week 18
Safety and tolerability: adverse events
時間枠:From treatment initiation through week 18

Frequency and severity of adverse events, serious adverse events, dose interruptions, and discontinuations throughout the study period. Summarized descriptively by event type, severity, causality, and outcome.

From treatment initiation through week 18
Safety and tolerability: laboratory values
時間枠:6 weeks after treatment initiation

Proportion of 6 week post-treatment initiation safety laboratory values that are outside pre-specified thresholds reported descriptively, including phenylacetate level > 500 µg/mL, phenylacetic acid-to-phenylacetylglutamine (PAA-to-PAGN) ratio > 1.5, bicarbonate level < 17 mEq/L, anion gap > 12 mEq/L, urine pH < 5.5, the combination of low carnitine (total carnitine level < 30 µmol/L OR free carnitine level < 20 µmol/L) PLUS an elevated esterified-to-free carnitine ratio > 0.4, and ALT or AST (exceeds 3× the upper limit of normal with symptoms, or exceeds 5× the upper limit of normal without symptoms). Each parameter is reported separately as the proportion of participants with values outside pre-specified thresholds.

6 weeks after treatment initiation
EEG: Delta spectral power
時間枠:Baseline and Week 18

Change in delta-frequency (2.5-4 Hz) EEG spectral power from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively as an exploratory biomarker of treatment response.

Baseline and Week 18
EEG: Delta-frequency autocorrelation
時間枠:Baseline and Week 18

Change in EEG autocorrelation at lags corresponding to 2.5-4 Hz from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively.

Baseline and Week 18
EEG: Spectral entropy
時間枠:Baseline and Week 18

Change in broadband (0-30 Hz) EEG spectral entropy from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively.

Baseline and Week 18
EEG: Combination of three measures
時間枠:Baseline and Week 18

Proportion of 1-second EEG segments meeting all three pre-specified thresholds simultaneously (delta power >105,000 μV², autocorrelation >0.410, spectral entropy ≤3.16) in ≥3 channels, compared from baseline to week 18. Analyzed descriptively as an exploratory biomarker outcome.

Baseline and Week 18
Concurrent randomized seizure comparison
時間枠:Week 6

Proportion of participants achieving ≥50% seizure reduction in Arm A (on treatment) versus Arm B (observation period) at week 6, reported as absolute risk difference, relative risk reduction, and number needed to treat, with 95% confidence intervals. Quantitative EEG measures (delta-frequency spectral power, autocorrelation at 2.5-4 Hz lags, and broadband spectral entropy) will be compared between arms at week 6 as an exploratory biomarker. Analyzed descriptively.

Week 6
Arm A within-person early vs. stable dose seizure comparison
時間枠:Weeks 0-2 and weeks 14-18

Mean weekly seizure frequency during early treatment (weeks 0-2) compared to the stable dose period (weeks 14-18) in Arm A participants. Analyzed descriptively.

Weeks 0-2 and weeks 14-18
Arm B within-person seizure change
時間枠:Weeks 0-6 and weeks 12-18 of treatment

Seizure frequency trajectory in Arm B, estimated using a segmented regression model assessing whether the pre-treatment slope is flat and characterizing the post-treatment slope through the stable dose period (weeks 12-18). Analyzed descriptively.

Weeks 0-6 and weeks 12-18 of treatment
Trajectory replication across arms
時間枠:Weeks 0-18

Comparison of post-treatment slopes from the segmented regression model in Arm A and Arm B, offset by 6 weeks, assessing whether the two arms show comparable seizure frequency trajectories following treatment initiation. Analyzed descriptively.

Weeks 0-18

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Kristen Barbour, MD、This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2029年3月1日

研究の完了 (推定)

2032年10月1日

試験登録日

最初に提出

2026年4月9日

QC基準を満たした最初の提出物

2026年9月24日

最初の投稿 (実際)

2026年9月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月24日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する